Broad use of artificial intelligence brings challenges around transparency and risks of failure, regulators say
The widespread use of artificial intelligence software in medicine development creates “regulatory challenges” that require new guidelines and stronger governance, according to an international group of medicines regulators.
The International Coalition of Medicines Regulatory Authorities issued recommendations around the use of AI in a report, published on 16 August, of a horizon-scanning exercise carried out by several of its members under the leadership of the European Medicines Agency.